CT-based radiomics and clinical characteristics for predicting bone metastasis in lung adenocarcinoma patients.

Abstract

The occurrence of bone metastasis (BM) will seriously shorten the survival time of lung adenocarcinoma patients and aggravate the suffering of patients. Computed tomography (CT)-based clinical radiomics nomogram may help clinicians stratify the risk of BM in lung adenocarcinoma patients, thereby enabling personalized individualized clinical decision making. A total of 501 patients with lung adenocarcinoma from March 2017 to March 2019 were enrolled in the study. Based on plain chest CT images, 1130 radiomics features were extracted from each lesion. One-way analysis of variance (ANOVA) and least absolute shrinkage selection operator (LASSO) algorithm were used for radiomics features selection. Univariate and multivariate analyses were used to screen for clinical characteristics and identify independent predictors of BM. Three models (radiomics model, clinical model and combined model) were constructed to predict BM in lung adenocarcinoma patients. Receiver operating characteristic (ROC) curve and decision curve analysis (DCA) were used to evaluate the performance of the three models. The DeLong test was used to compare the performance of the models. Finally, the clinical model for predicting BM in lung adenocarcinoma patients was constructed based on 5 independent predictors: cytokeratin 19-fragments (CYFRA21-1), stage, Ki-67, edge, and lobulation. The radiomics model was constructed based on 5 radiomics features. The combined model incorporating clinical independent predictors and radiomics was constructed. In the validation cohort, the area under the curve (AUC) of the clinical model, radiomics model and combined model was 0.824, 0.842 and 0.866, respectively. Delong test showed that in the training cohort, the AUC values of the radiomics model and the combined model were statistically different (P=0.03), and the AUC values of the other models were not statistically different. DCA showed that the nomogram had a highest net clinical benefit. The CT-based clinical radiomics nomogram can be used as a non-invasive and quantitative method to help clinicians stratify the risk of BM in patients with lung adenocarcinoma, thereby enabling personalized clinical decision making.